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Main Document (includes tables and figure legends) 
 
Running header: Atacicept in rheumatoid arthritis 
 
Abstract 
Background: Recent data suggest a key role for B cells in the pathogenesis of many 
autoimmune diseases including rheumatoid arthritis (RA), and biological therapies 
targeting B cells are promising treatments for patients with RA. Atacicept inhibits B 
cell maturation, differentiation and survival, and immunoglobulin production by 
depriving B cells of growth and development signals. Therefore, atacicept may 
represent an effective strategy in RA treatment. 
Objective: To evaluate the potential value of atacicept in RA treatment based on 
preclinical and clinical studies. 
Methods: Preclinical and clinical data on atacicept were identified using PubMed and 
systematically reviewed.   
Results/conclusion: Preclinical and clinical studies show that atacicept is well 
tolerated, with no increased incidence of infections. Atacicept displays non-linear 
pharmacokinetics, with a more than dose-proportional increase in free drug and less 
than dose-proportional, saturated increase in atacicept–ligand complex. Overall, the 
pharmacokinetic profiles of atacicept were consistent, dose-related and predictable. 
Dose-dependent reductions in immunoglobulins and other biomarkers, including 
rheumatoid factor, occurred rapidly but returned to baseline after discontinuation. 
There was a biphasic response in B cell number, but no effect on other leucocytes. 
Atacicept improved the signs and symptoms of RA, although larger studies are 
needed to confirm its efficacy and its optimal use. 
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Keywords: atacicept; B cells; biological therapies; growth factors; rheumatoid 
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1. Introduction 
Rheumatoid arthritis (RA) is characterised by chronic synovial inflammation, leading 
to pain and damage of the affected joints and cartilage. During the past 25 years, 
significant advances have been made in the treatment of RA. First-line treatment is 
usually with disease-modifying antirheumatic drugs (DMARDs) such as methotrexate 
(MTX), sulphasalazine and leflunomide [1], with introduction of tumour necrosis 
factor (TNF)- blockade therapies if patients continue to have active disease. The 
introduction of TNF- blockers represented a new era of targeted biological therapies. 
Unlike traditional DMARDs, which result in non-specific suppression of the immune 
system [2], biological therapies target specific molecules or cells based on our 
improved understanding of the pathogenesis of RA. However, in a proportion of 
patients with RA, TNF- blockade fails to achieve a satisfactory clinical 
improvement or a sustained clinical response over time. Furthermore, the use of anti-
TNF- is associated with increased risk of infections [3, 4].  
In this regard, although RA has been considered primarily a T cell-mediated disease, 
recent data support a key role for B cells [5, 6]. The success of B cell-depleting 
therapy with rituximab underscored further the importance of B cells in the 
pathogenesis of RA [7]. 
 
2. Review  
2.1 Overview of the market 
Rituximab was the first licensed B cell-depleting therapy for the treatment of RA.  It 
was initially developed for the treatment of non-Hodgkin’s lymphoma (NHL) [8], but 
was found to be effective in several autoimmune disorders, including RA [9]. 
Rituximab is licensed for use in combination with methotrexate for the treatment of 
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adults with severe, active RA who have had an inadequate response to, or intolerance 
of, other DMARDs, including at least one TNF- inhibitor [10]. Rituximab has 
proven efficacy in patients with RA refractory to TNF- blockers, with approximately 
50% of patients achieving at least a 20% improvement in American College of 
Rheumatology criteria (ACR20) [11, 12]. Complete remission after a single course of 
rituximab treatment is rare, however, and most patients experience disease relapse 
between 6 and 12 months, even when peripheral B cell number remains suppressed 
[13–17]. Re-treatment with rituximab may be effective and appears safe [18], but 
alternative treatments that target B cells may also be efficacious in this patient 
population. In this regard, several other B cell-targeting biological therapies have 
been developed. These include other monoclonal antibodies (mAbs) that target CD20 
or other B cell-surface molecules (e.g. CD19 and CD22). An alternative approach to 
decreasing B cells is to target the B cell-activating factor, B lymphocyte stimulator 
(BLyS; also known as B cell-activating factor belonging to the tumour necrosis family 
(BAFF), TALL-1, zTNF4 and CD257) and the related cytokine APRIL (a 
proliferation-inducing ligand or CD256) by blocking the interactions between 
BLyS/APRIL and their receptors [19]. 
 
2.2 Introduction to the compound 
Atacicept is a fully human, recombinant receptor–immunoglobulin (Ig) fusion protein. 
Biochemically, atacicept is a homodimeric fusion protein (molecular mass, 73.4 kDa 
[20]) containing the extracellular, BLyS/APRIL-binding domain of the TACI 
(transmembrane activator and calcium-modulating and cyclophilin-ligand interactor) 
molecule and the Fc portion of human IgG1. Atacicept binds to the B cell growth 
factors BLyS and APRIL (Figure 1) [21]. BLyS acts on B cells to enhance maturation, 
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proliferation, survival, antigen presentation and antibody class-switching at various 
stages of B cell development [22]. APRIL, a homologue of BLyS, has a similar action 
on B cells [23]. Both BLyS and APRIL are produced by a wide variety of cell types, 
and can form homotrimers as well as heterotrimers (Figure 2). BLyS and APRIL exert 
their biological function by signalling through their receptor proteins: TACI and 
BCMA (B cell-maturation antigen) receptors. BLyS also has a high affinity for BAFF 
receptors (BAFF-R), and APRIL can bind with low affinity to heparan–sulphate 
proteoglycans. TACI is a membrane receptor expressed on specific populations of B 
cells and on activated T cells. Indeed, it has been reported that BLyS can co-stimulate 
T cells under certain circumstances [24]. In B cells, TACI is expressed weakly on 
immature transitional type-1 B cells, and at high levels on immature transitional type-
2 B cells, marginal-zone B cells and activated B cells, but not on germinal-centre 
(GC) B cells  [24]. However, TACI expression is induced upon the differentiation of 
GC B cells into plasma cells [25]. The expression of B cell growth-factor receptors 
and CD20 on B cell subsets is summarised in Table 1. As a result of differential 
responsiveness of to BLyS and APRIL, atacicept inhibits the generation of 
autoreactive plasma cells that produce autoantibodies, but spares pro- and pre-B cells 
and some immature B cells [23]. In vitro, atacicept inhibits the proliferation and 
differentiation of naïve B cells and GC B cells, as well as the generation of plasma 
cells [25]. Furthermore, Benson et al. showed that simultaneous inhibition of BLyS 
and APRIL in mice is necessary for the decrease in plasma cells, but does not 
decrease memory B cells [29], although caution is needed when extrapolating these 
findings to the clinic. This decrease is reversible as there is a rapid recovery of B cell 
numbers upon discontinuation of atacicept [30]. Thus, atacicept acts as a competitive 
antagonist to BLyS and APRIL and represents a promising novel strategy in the 
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management of diseases characterised by B cell hyperactivity, such as RA, systemic 
lupus erythematosus (SLE) and B cell malignancies. 
In many autoimmune rheumatic diseases, including RA, elevated levels of circulating 
BLyS/APRIL heterotrimers were detected in patient serum [31]. Furthermore, 
transgenic mice overexpressing BLyS exhibit a lupus-like syndrome and have high 
titres of anti-double-stranded DNA antibodies, rheumatoid factor (RF) and 
proteinuria, as well as Ig deposition in the kidneys and glomerulonephritis [32]. Half 
of these animals also have elevated serum Ig levels. These observations suggest that 
BLyS and APRIL may play an important role in the pathogenesis of RA and SLE, 
although their precise role remains under debate. For instance, Stol et al showed that 
serum APRIL levels inversely correlated with serum anti-dsDNA titres or disease 
activity in SLE [33], and APRIL may have both pro- and anti-inflammatory activities 
in RA [34]. Furthermore, the network that governs B cell survival is complex and has 
not been fully defined (reviewed in [35]). For instance, data from TACI knockout 
models suggest that TACI plays an inhibitory role in B cell development [36]. 
Therefore, targeting BLyS/APRIL by atacicept may not produce the anticipated 
effects.  
To evaluate the potential use of atacicept in RA treatment based on available 
preclinical and clinical studies, published literature on atacicept and TACI:Fc fusion 
proteins in preclinical and clinical studies was identified using the PubMed database 
and systematically reviewed. The search was limited to literature published in English 
using the search terms atacicept, TACI-Ig and TACI plus Fc.  
 
2.3 Pharmacodynamics (PD) 
2.3.1 Preclinical data 
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Atacicept was shown to inhibit disease progression in a murine model of collagen-
induced arthritis [23]. Naïve mice were treated with 100 µg of human TACI-Ig, 
human Ig or phosphate-buffered saline three times weekly for two weeks. Disease 
incidence and the severity of inflammation were lowered when atacicept was 
administered both before disease onset and after disease was established. Atacicept 
inhibited the production of collagen-specific antibodies and a decreased number of 
follicular B cells was observed in the spleen.  
Data from the use of atacicept in other animal models have provided further valuable 
information on the pharmacodynamics of the drug. For instance, in a murine model of 
SLE, treatment with 20 or 100 g of atacicept three times weekly for 5 weeks led to a 
significant reduction of proteinuria for up to 10 weeks [37]. The higher dose regimen 
also significantly increased the survival of animals, and this effect was correlated with 
a decrease in peripheral blood B cells (a 53% reduction compared with controls) and 
persisted for 5 weeks post-treatment. In another study, atacicept (0.4, 2 or 10 mg/kg) 
was administered to mice either as a single dose or as repeated doses on alternate days 
for 2, 4 and 26 weeks [30]. In the 26-week study, antibodies against atacicept were 
detected in animals treated at the lower doses but not the 10 mg/kg dose, and were 
associated with higher than expected levels of IgG and IgM. 
 
2.3.2 Clinical data 
2.3.2.1 Healthy volunteers 
In a phase I, double-blind, dose-escalating, sequential-dose study, 23 healthy male 
volunteers received a single subcutaneous injection of 2.1, 70, 210 or 630 mg of 
atacicept or placebo and were followed up for 7 weeks [38]. A single dose of atacicept 
resulted in a dose-dependent reduction of serum IgM levels for up to 210 days post-
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dose; the highest dose was associated with a 23% decrease in IgM levels 2 weeks 
after treatment [38]. There were no treatment-related effects on IgG levels or 
lymphocyte subpopulations. Biological effects were not apparent for placebo and the 
2.1 mg atacicept dose. No other clinically significant changes in laboratory 
parameters or vital signs were observed in any treatment group. 
 
2.3.2.2 RA patients 
A phase Ib, randomised, double-blind, placebo-controlled, dose-escalating study was 
conducted in 73 RF-positive patients with active, moderate-to-severe RA [39, 40]. 
The patients were given atacicept or placebo as single doses (70, 210 or 630 mg) or as 
repeated doses (3 doses of 70 or 210 mg, or 7 doses of 420 mg) every fortnight. IgM, 
IgA and IgG levels fell rapidly in a dose-dependent manner after the first dose of 
atacicept, and continued to decrease with subsequent doses. In patients who received 
7  420 mg of atacicept, IgM, IgA and IgG levels dropped by 54%, 37% and 21%, 
respectively from baseline (Table 2). The levels of all Ig isotypes began to recover at 
the end of the dosing regimen and were at, or close to, baseline values 12 weeks after 
the last dose. RF levels of all three classes were consistently reduced (between 41 and 
44% of baseline) after 7  420 mg atacicept (Table 2) and returned to baseline levels 
within 2–3 months after the treatment discontinued. The levels of anti-cyclic 
citrullinated peptide (CCP) antibodies were unaffected except in patients receiving the 
maximum dose of atacicept, in whom levels were consistently decreased (Table 2). 
Atacicept treatment led to a biphasic response in the number of total and mature B 
cells, as well as memory, immature and naïve B cells, in the peripheral blood. The 
initial phase consisted of a transient dose-related increase in cell numbers, with 
memory B cells displaying the highest median percentage change, and mature B cells 
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the lowest. The second phase consisted of a sustained, dose-related reduction of B 
cells to below pre-dose levels. No anti-atacicept antibodies were detected and no 
changes in vital signs were observed.  
 
2.4 Pharmacokinetics (PK) 
2.4.1 Healthy volunteers 
In 23 healthy volunteers receiving a single subcutaneous injection of 2.1, 70, 210 or 
630 mg of atacicept, serum levels of free drug were dose-dependent and reached their 
maximum at 16 hours post-injection [38]. BLyS–atacicept complex levels persisted 
longer, however, peaking between 14 and 35 days post-dose, and were measurable for 
up to 210 days. With increasing doses, increases in the maximum serum concentration 
and the area under the concentration–time curve were non-linear, indicating that there 
was a decrease in apparent clearance with increasing dose. These observations suggest 
that increasing the atacicept dose beyond the amount necessary for saturation would 
not lead to a significant increase in the atacicept–BLyS complex profiles and is thus 
unlikely to bring additional clinical benefit. The median terminal elimination half-life 
of atacicept was 12.4 days. The value was slightly higher in the higher-dose arms, 
which may be due in part to the sampling scheme and in part to the high proportion of 
terminal values below the lower limit of quantification in the lower-dose arms. 
 
2.4.2 RA patients 
In the phase 1b study of 73 patients with RA, atacicept also displayed multiphasic PK 
with a greater than dose-proportional increase in free atacicept. Peak concentrations 
were reached approximately 24 hours after the first dose, followed by at least one 
distribution phase (complete by 7–14 days after administration) and a long terminal 
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elimination phase (terminal half-life of 25–63 days). There was a less than dose-
proportional, saturated increase in atacicept–BLyS complex. Accumulation of 
atacicept–BLyS complex continued throughout the entire dosing period. Atacicept 
was also detectable in two of four patients who underwent synovial fluid sampling, 
with levels similar to the measured serum concentrations in the same patient at the 
same time point. The PK profiles of atacicept were consistent and predictable across 
all doses and between single and multiple doses [39, 40]. The PK profile of atacicept 
7  420 mg after the first and last dose is shown in Table 3. 
 
2.5 Clinical efficacy 
2.5.1 Rheumatoid arthritis 
In the phase 1b study, atacicept-treated patients in the 7  420 mg group had a mean 
Disease Activity Score using 28 joint counts (DAS28) of 6.4 at baseline, which 
improved to 5.1 on day 85 and persisted beyond treatment cessation [39]. No change 
was seen in patients who received placebo. During the 3 months of atacicept 
treatment, 32% of patients achieved an ACR20 response, with two achieving an 
ACR70 response. The effect on the ACR20 response occurred as early as 2 weeks 
after treatment initiation. 
 
2.5.2 Ongoing clinical studies in RA 
Given the positive results in the early studies, several phase II clinical trials are 
currently ongoing and include: 
(i) Dose-finding study (ClinicalTrials.gov Identifier: NCT00430495) 
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This is a multicentre, randomised, double-blind, placebo-controlled study started in 
2006, testing three dose levels of atacicept in 300 patients with RA who had 
inadequate responses to TNF- blockers.  
(ii) Combination study with rituximab (ClinicalTrials.gov Identifier: NCT00664521) 
Two recent studies demonstrated that the serum levels of BLyS were significantly 
increased after treatment with rituximab [41, 42]. Furthermore, the serum levels of 
APRIL in patients with RA were found to be 10-fold higher than normal controls and 
remained elevated after treatment with rituximab. These observations indicated that 
atacicept may be a useful adjunct to rituximab therapy. Therefore, a phase II clinical 
trial was initiated to evaluate the safety and efficacy of combined treatment with 
atacicept and rituximab in patients with RA receiving treatment with rituximab. 
(iii) Study in anti-TNF- naïve patients with moderate-to-severe RA and an 
inadequate response to methotrexate (ClinicalTrials.gov Identifier: NCT00595413) 
This is a phase II study investigating the efficacy of atacicept compared with placebo 
in the treatment of patients with RA with inadequate response to MTX and no 
previous exposure to anti-TNF- therapy. 
 
2.6 Safety and tolerability 
2.6.1 Healthy volunteers 
In the study of 23 healthy volunteers given a single subcutaneous dose of atacicept (at 
2.1, 70, 210 or 630 mg) or placebo, the adverse events were similar between all 
groups [38]. Mild-to-moderate, transient adverse events were reported in 
17 participants (73.9%); the most frequent events were headache, sore throat and head 
cold. There was no correlation between atacicept dose and any adverse event. 
Participants who had levels of atacicept–BLyS complex above baseline at week 7 
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entered an extension period, with PK/PD sampling at monthly intervals. No 
treatment-related adverse events were reported during the extension phase. During the 
main study and extension phase there were no deaths, no serious or life-threatening 
adverse events, no clinically significant changes in the measured safety parameters 
and no withdrawals relating to adverse events. Injection-site pain immediately after 
injection (assessed by 100 mm visual analogue scale [VAS]) was reported by 
16 participants. The highest VAS scores for pain were observed in participants in the 
210 mg and 630 mg groups. The higher doses were also more likely to be associated 
with mild, acute or prolonged injection-site redness, which was probably related to the 
greater injection volumes and number of injections. 
 
2.6.2 Rheumatoid arthritis 
In the phase Ib clinical trial of 73 patients with RA [39], atacicept was found to be 
well tolerated. Adverse events were reported by 32 patients (44%); only three events 
were considered to be severe (arthralgia in the 3  210 mg cohort; rheumatoid nodule 
and an RA exacerbation in the 7  420 mg cohort). There was no significant 
difference in the frequency of infection-related events between patients who received 
atacicept and those who received placebo, or between treatment groups. No infection-
related events were considered serious or severe. One serious adverse event 
(pneumothorax) and one death (lung cancer) occurred during the study; neither was 
considered to be related to treatment. Local injection-site symptoms were reported in 
24 patients, the most frequent being mild-to-moderate erythema (15 patients). VAS 
pain scores >0 were reported by 17 patients (median, 15 mm). 
 
2.6.3 Other conditions 
Page 13 of 32
URL: http://mc.manuscriptcentral.com/eobt  Email: Andrew.Murdock@informa.com
Expert Opinion On Biological Therapy
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
F
o
r P
eer R
eview
 O
n
ly
 13 
Atacicept has been investigated in a number of other conditions, including SLE, NHL 
and multiple myeloma. These studies provide valuable additional clinical data on the 
safety and tolerability of atacicept. In a phase Ib study, 47 patients with mild-to-
moderate SLE received either single doses of atacicept (0.3, 1, 3 or 9 mg/kg), or 
weekly doses of atacicept (1 or 3 mg/kg) or placebo, for 4 weeks [43]. There were no 
statistical differences in the frequency or type of adverse events, including infections, 
between the placebo and atacicept groups. Adverse events were reported by 78% of 
patients in the single-dose cohorts and by 77% of patients in the repeated-dose 
cohorts. All events were mild or moderate in severity, except for an event of severe 
paraesthesia in a patient receiving repeated-dose placebo. There were no withdrawals 
or discontinuations related to adverse events, and no serious adverse events in patients 
receiving atacicept. Injection-site redness was observed in 50% of all patients 
receiving atacicept, with no itching or severe injection-site reactions reported. No 
clinically significant changes in vital signs or laboratory parameters were reported. 
In studies of 15 patients with relapsed or refractory B cell NHL [44] and 16 patients 
with advanced multiple myeloma or Waldenström’s macroglobulinaemia [45], 
participants were given atacicept (2, 4, 7 or 10 mg/kg) weekly for 5 weeks. Patients 
responding or with stable disease were eligible for further study treatment for up to 
24 weeks or until disease progression. In both studies, atacicept was well tolerated, 
with no dose-limiting toxicities observed. Most adverse events were of mild or 
moderate severity with fatigue, injection-site bruising, dyspnoea, anorexia, diarrhoea 
and nausea being the most frequent. Fatigue was the only adverse event to be 
considered related to treatment in four NHL patients. No serious adverse events were 
considered to be linked to atacicept treatment. Few infections were reported; all were 
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mild or moderate in severity and none was considered related to atacicept treatment. 
No anti-atacicept antibodies were detectable at the end of the study. 
 
3. Conclusion 
B cell-targeting therapies have been proven to be an effective approach to treating 
RA. BLyS and APRIL, which appear to be important in the pathogenesis of RA, bind 
to specific B cell receptors such as the TACI receptor and mediate B cell function, 
survival and antibody production. Atacicept, a recombinant receptor-Ig fusion protein, 
binds BLyS and APRIL and inhibits plasma cell and late-stage B cell development 
and survival but has no effect on B cell progenitors and memory cells. In clinical 
studies, atacicept is well tolerated in patients with RA with consistent and dose-
related pharmacokinetic profiles. Dose-dependent decreases in immunoglobulins and 
relevant biomarkers, and reductions in mature B cells, were observed in atacicept-
treated patients with RA. Initial clinical improvements in RA symptoms were also 
observed although data from larger clinical trials are needed to confirm the efficacy of 
atacicept. Results from these early clinical trials demonstrate the potential value of 
atacicept in the treatment of RA. 
  
4. Expert opinion 
There is now an increasing body of evidence to support a key role for B cells in the 
pathogenesis of RA. Furthermore, data from animal models and clinical studies also 
support an important role for the B cell growth factors BLyS and APRIL in the 
development of autoimmune disease. As BLyS and APRIL enhance the maturation, 
survival and proliferation of B cells, and the generation of plasma cells, neutralisation 
of BLyS and APRIL activity by atacicept can inhibit the later stages of B cell 
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differentiation and reduce the number of circulating mature B cells and plasma cells, 
and reduce Ig levels. Indeed, data from preclinical models showed that atacicept 
predominantly inhibits mature B cells and plasma cells, without affecting other 
lymphoid or myeloid populations. The safety profile of atacicept is good, and data 
from early-phase clinical trials are promising for using atacicept in the treatment of 
RA. Very recently, La and colleagues showed that serum levels of BLyS remained 
elevated in RA patients who did not respond to TNF- blockade therapies, whereas 
serum BLyS levels declined in good responders [46]. Therefore, inhibition of BLyS 
activity by agents such as atacicept may be particularly beneficial for patients who do 
not respond to anti-TNF therapies. 
 
Interest in the role of B cells in the pathogenesis of RA has led to the development of 
several other potential therapeutic agents that specifically target B cells by distinct 
mechanisms. Ocrelizumab [47] and ofatumumab [48] are fully humanised anti-CD20 
mAbs. Since CD20 appears at the pre-B stage and disappears during differentiation to 
plasma cells, treatment with anti-CD20 therapies will not deplete stem cells and 
plasma cells, and serum Ig levels do not fall substantially during treatment. Indeed, 
the sparing of pathogenic antibody-producing plasma cells with anti-CD20 biological 
therapies may be one of the explanations for the disease relapse observed in RA 
patients treated with rituximab. In contrast, atacicept targets different subsets of B 
cells compared with rituximab, inhibiting B cells throughout their differentiation from 
naïve B cells to plasma cells. Therefore, atacicept may provide a clinically relevant 
decrease in pathogenic B cells while sparing some non-pathogenic B cells. In 
addition, atacicept may be safer than anti-CD20 monoclonal antibodies because of the 
less pronounced and prolonged B cell reductions. When used in combination with 
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anti-CD20 therapy, atacicept may facilitate broader and more prolonged B cell 
depletion. However, whether these differences will translate in terms of relative risk 
and benefit remains to be determined in controlled clinical trials. 
 
Another biological therapy targeting B cell growth factors that has been tested in 
rheumatic diseases is belimumab, a humanised mAb against BLyS. As such, it 
inhibits B cell stimulation by BLyS, but not APRIL. In vivo models have 
demonstrated that antagonism of BLyS alone has no effect on bone marrow plasma 
cells whereas simultaneously blocking both APRIL and BLyS reduces bone marrow 
plasma cells [29]. Thus, the ability to inhibit the activity of APRIL in addition to 
BLyS by atacicept may prove advantageous, particularly in conditions such as RA 
and SLE, in which excess APRIL may play a role in pathogenesis [42, 49]. It remains 
to be seen, however, whether this difference will translate into biological or clinical 
benefits. In a phase II clinical study in patients with RA, belimumab demonstrated 
only a modest clinical benefit [50]. Reductions in B cells and rheumatoid factors were 
observed but ACR responses were relatively low with only a 13% increase with 
belimumab over placebo in the number of patients achieving an ACR20 response. 
Other B cell-targeting therapies that are currently being evaluated for the treatment of 
RA include epratuzumab (a humanised mAb against B cell-restricted 
sialoglycoprotein, CD22) and single-chain polypeptides such as TRU-015. 
 
Despite promising data from early clinical trials, the efficacy of atacicept in the 
treatment of RA needs to be confirmed in clinical trials of larger cohorts. 
Furthermore, the optimal timing, dose and dosing regimen for using atacicept in the 
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treatment of RA remain to be determined [51]. Future clinical trials are also needed to 
identify predictors of response to enable the optimal use of the therapy. 
 
Little is known about the medium- and long-term effects on the immune system of 
neutralising the activity of BLyS and APRIL. Atacicept has been shown to profoundly 
decrease Ig levels, and therefore concerns about long-term use exist, particularly 
regarding the risk of infections and possibly malignancies, which will need to be 
assessed by clinical studies in larger cohorts for longer durations.  
 
Although anti-atacicept antibodies have so far not been detected in clinical trials, they 
were detected after long-term exposure in animals [30, 36] and had a neutralising 
effect on the administered drug. The co-administration of methotrexate may be useful 
in reducing the formation of neutralising antibodies and improving efficacy.  
 
Finally, atacicept may also be efficacious in other autoimmune conditions such as 
SLE, multiple sclerosis, Sjögren’s syndrome, systemic sclerosis and 
glomerulonephritis, as well as B cell malignancies.  
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Table 2. Pharmacodynamic parameters in patients receiving placebo or atacicept 7  
420 mg at 2-weekly intervals (data from Tak et al. [39])  
Atacicept 7  420 mg Placebo 
Parameter (% of baseline value) Day 85 Day 165 Day 85 Day 165 
Median Ig levels 
 IgA 
 IgG 
 IgM 
 
62 
79 
46 
 
85 
94 
74 
 
99 
99 
99 
 
103 
103 
102 
Median RF levels 
 IgA-RF 
 IgG-RF 
 IgM-RF 
 
62 
59 
59 
 
83 
71 
99 
 
100 
91 
110 
 
 
99 
98 
108 
 
Median ACPA 75 84 103 99 
B cells 
 Total (CD19+) 
 Mature (IgD+/CD27–) 
 
94 
72 
 
75 
64 
 
124 
138 
 
190 
239 
Day 85 represents the nadir in the immunoglobulin profiles; ACPA, anti-citrullinated 
protein antibodies; Ig, immunoglobulin; RF, rheumatoid factor. 
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Table 3. Pharmacokinetic parameters in patients receiving atacicept 7  420 mg at 2-
weekly intervals (data from Nestorov et al. [40]) 
Parameter (mean ± SD) After first dose After last dose 
Free atacicept 
 t½ (hours) 
 
tmax (hours) 
 Cmax (ng/mL) 
 AUC0-336 (mg·h/L) 
 
107 ± 25.3 
26.5 ± 7.6 
5600 ± 3090 
433 ± 177 
 
888 ± 301 
2040 ± 5.7 
5280 ± 2480 
924 ± 418 
Composite atacicept 
 t½ (hours) 
 
tmax (hours) 
 Cmax (ng/mL) 
 AUC0-336 (mg·h/L) 
 
97.6 ± 23.2 
28 ± 9 
7390 ± 3700 
783 ± 295 
 
885 ± 140 
2040 ± 7.6 
7320 ± 3530 
1650 ± 504 
AUC336, area under the concentration–time curve from time 0 to 336 hours; Cmax, 
maximum serum concentration; SD, standard deviation; t½, terminal half-life; tmax, 
time to Cmax. 
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Figures legends 
Figure 1. Mode of action of the B cell-targeting therapies atacicept (a) and rituximab 
(b) with a black cross indicating the affected B cell stages. Atacicept binds BLyS (B 
lymphocyte stimulator) and APRIL (a proliferation-inducing ligand) leading to 
reductions in mature, activated and antibody-producing B cell populations. Rituximab 
targets CD20 receptors on B cells, which are expressed on pre- through to memory B 
cells. 
 
Figure 2. BLyS and APRIL are secreted by monocytes, neutrophils, dendritic cells 
and T cells. Expression of BLyS and APRIL is dependent on the cytokine 
environment and is stimulated by interferon (IFN)-, IFN- and interleukin (IL)-10, 
and also by CD40 for dendritic cells. Soluble BLyS and APRIL usually form 
biologically active homotrimers, but can also form heterotrimers (HTs). BLyS, 
APRIL and HTs bind to specific B cell receptors (TACI, BCMA and BAFF-R) and 
trigger signals regulating B cell function (including proliferation and class switching 
to produce immunoglobulins) and survival. Binding of BLyS and APRIL to TACI, 
BCMA and BAFF-R induces the NF-B signalling pathway, which plays a pivotal 
role in mediating inflammatory responses and facilitating adaptive immunity. 
Interaction with BCMA and TACI result in up- or downregulation of members of the 
Bcl-2 family of proteins that are involved in cell death, proliferation, survival, cell–
cell interactions etc. APRIL also binds to proteoglycans (not shown), but the 
significance of this binding is not yet clear. Thus, BLyS and APRIL are key 
stimulators of B cell maturation, survival and proliferation, and are therefore targets 
for autoimmune disease therapy such as RA.  
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Title: Atacicept, a novel B cell-targeting biological therapy for the treatment of 
rheumatoid arthritis 
Abbreviations: 
ACR20 At least a 20% improvement in the American College of 
Rheumatology criteria 
APRIL  A proliferation-inducing ligand 
BAFF  B cell-activating factor belonging to the tumour necrosis family 
BAFF-R BAFF receptor 
BCMA B cell-maturation antigen 
BLyS  B lymphocyte stimulator 
CCP  Anti-cyclic citrullinated peptide 
DAS  Disease activity score 
DMARD Disease-modifying antirheumatic drug 
GC  Germinal centre 
Ig  Immunoglobulin 
mAb  Monoclonal antibody 
MTX  Methotrexate 
NHL  Non-Hodgkin’s lymphoma 
PD  Pharmacodynamics 
PK  Pharmacokinetics 
RA  Rheumatoid arthritis 
RF Rheumatoid factor 
SLE Systemic lupus erythematosus 
TACI Transmembrane activator and calcium-modulating and cyclophilin-
ligand interactor 
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TNF  Tumour necrosis factor 
VAS  Visual analogue scale 
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